Cameron McIntyre, PhD - Deep Brain Stimulation Informatics

Tuesday, March 14, 2017 - 12:00pm to 1:00pm
BPC 170 (Lee T. Todd Building)


Deep brain stimulation (DBS) technology has made an impressive impact on clinical medicine, but after ~25 year of experience and over 125,000 cases, variability in clinical outcomes remains an issue of concern. While this probably isn't surprising for emerging indications such as depression, it is unfortunate (bordering on unacceptable) for established applications such as Parkinson's disease. One possible explanation for this outcome variability is the lack of DBS-specific informatics toolboxes and/or database systems that could be used to identify patterns and define best practices. The concept is to integrate data like pre-operative clinical assessments and surgical targeting images with post-operative clinical outcome metrics and stimulation parameter settings. While a comprehensive DBS informatics system doesn't currently exist, components are available and their integration is underway. Such an assembly will facilitate application of machine learning algorithms to help the DBS community improve patient selection, surgical targeting, and device programming to optimize clinical outcomes.

Bio Sketch

Cameron McIntyre, PhD, was born in Marietta, OH in 1974. He received his BS and PhD in Biomedical Engineering from Case Western Reserve University in 1997 and 2001, respectively. His doctoral research focused on the biophysics of the interaction between electric fields and neurons. From 2001 to 2003, he performed postdoctoral training at Johns Hopkins University and Emory University where he studied deep brain stimulation (DBS). In 2003 he joined the faculty at the Cleveland Clinic Foundation and maintained a laboratory there until 2012. In 2013, the McIntyre lab moved to Case Western Reserve University to create the Case Neuromodulation Center.

Cameron is currently appointed as the Tilles-Weidenthal Professor in the School of Medicine Department of Biomedical Engineering. Financial support for the lab has been primarily derived from multiple National Institutes of Health research grants that focus on the neurophysiological effects and engineering design of DBS systems. The fundamental goal of the research program is to use knowledge on the therapeutic mechanisms of DBS to better engineer the next generation of DBS technology. Of particular note, the McIntyre lab invented the GUIDE DBS clinical programming system which was commercialized by the spin-off company IntElect Medical Inc., then acquired by Boston Scientific Neuromodulation Corp and now has CE Mark approval in Europe.